Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 5, 2002, Pages 271-278

  Konstantinov, S ^a,d   Kostovski, A ^a   Topashka Ancheva, M ^b   Genova, M ^c   Berger, M ^d  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b INSTITUTE OF BIODIVERSITY AND ECOSYSTEM RESEARCH   (Bulgaria)

^c National Center of Clinical and Transfusion Hematology   (Bulgaria)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Bendamustine; Clastogenic effect; In vitro cytotoxicity; Lymphoid cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKYLATING AGENT; ANTIMETABOLITE; BENDAMUSTINE; DNA FRAGMENT; LOMUSTINE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PURINE;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELL CYCLE G1 PHASE; CELL ISOLATION; CELL NUCLEUS; CELL STRAIN HL 60; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME DEGRADATION; FEMALE; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOID CELL; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; STAINING; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; BREAST NEOPLASMS; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; LEUKEMIA; MICE; NITROGEN MUSTARD COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0036275553     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0331-8     Document Type: Article

References (36)

1. Vergleichsuntersuchungen zwischen cytostasan und cyclophosphamid bei der chronischen lymphadenose, dem palsmozytom, der lymphogranulomatose und dem bronchialkarzinom
2. Bendamustine
3. Study on the long-term toxic efficacy of cytosine-arabinoside in Sprague-Dawley rats
4. Long-term toxicology effects of prednimustine in comparison with chlorambucil, prednisolone, and chlorambucil plus prednisolone in Sprague-Dawley rats
5. Bendamustine therapy in advanced refractory chronic lymphocytic leukemia (CLL)
6. Bendamustine vs. Melphalan in the primary treatment of multiple myeloma (MM). A randomized prospective study
7. New drugs in the treatment of Hodgkin's disease
8. Bendamustine, a low toxic nitrogen mustard derivative with high efficiency in malignant lymphomas
9. Therapieergebnisse und toxische nebenwirkungen der kombination cytostasan, adriamycin und vincristin als "second-line" therapie beim metastatischen mammakarzinom
10. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine
11. Zur rezidivtherapie mit bendamustin bei patienten mit non-Hodgkin-lymphomen von niedrigem malignitätsgrad und plasmozytomen
12. Relapse therapy with bendamustine in patients with low-grade non-Hodgkin's lymphoma (NHL): Efficacy and toxicity
13. Bendamustine in untreated small cell lung cancer (SCLC): Efficacy and toxicity
14. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II study
15. Bendamustine, methotrexate, mitoxantrone and prednisolone (BMMP) for the treatment of relapsed or refractory high-grade non-Hodgkin's lymphoma
16. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia
17. Response of refractory and relapsed low grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia to Dexa-Bid, a bendamustinehydrochloride-containing regimen
18. Antitumor, nephrotoxic and clastogenic activity of cis-DDP with DDTC or NAC
19. Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow
20. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines
21. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells
22. Response and toxicity of chemotherapy with gemcitabine and bendamustine in advanced ovarian and breast cancer
23. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
24. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
25. Aminosäureantagonisten III
26. IMET 3393, ein neues zytostatikum aus der reihe der benzimidazol-loste
27. Arandomized multicenter study of bendamustine/prednisone versus melphalane/prednisone in the treatment of multiple myeloma
28. Pharmacological and clinical data of Bendamustin
29. Cytostasan (Bendamustin) in der therapie maligner lymphome
30. Bendamustine/mitoxantrone in the treatment of advanced breast cancer
31. Vergleichende untersuchungen über die zytostatische wirkung des neuen N-Lost-Derivats "IMET 3393" und endoxan an drei experimentellen mäusetumoren (Ehrlich-Karzinom, Sarkom 180, Leukämie LAJ I)
32. Repeated administration of short infusions of bendamustine: Phase I study in patients with advanced progressive tumours
33. Bendamustine in induction of apoptosis in B-cell chronic lymphocytic leukemia
34. Bendamustine hydrochloride activity against doxorubicine- resistant human breast carcinoma cell lines
35. Synthese eines potentiellen metaboliten des kanzerostatikums bendamustin (Cytostasen)